Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC) Meeting Abstract


Authors: Friedlander, T. W.; Milowsky, M. I.; Bilen, M. A.; Srinivas, S.; McKay, R. R.; Flaig, T. W.; Hoimes, C. J.; Balar, A. V.; Henry, E.; Petrylak, D. P.; Sasse, C.; Kataria, R. S.; Yu, Y.; Carret, A. S.; Rosenberg, J. E.
Abstract Title: Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)
Meeting Title: 2021 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 39
Issue: 15 Suppl.
Meeting Dates: 2021 Jun 4-8
Meeting Location: Virtual
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2021-05-20
Language: English
ACCESSION: WOS:000708120602276
DOI: 10.1200/JCO.2021.39.15_suppl.4528
PROVIDER: wos
Notes: Meeting Abstract: 4528 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg